Open Access. Powered by Scholars. Published by Universities.®
- Institution
- Publication Type
- File Type
Articles 1 - 2 of 2
Full-Text Articles in Medicine and Health Sciences
Evaluation Of 18F-Iam6067 As A Sigma-1 Receptor Pet Tracer For Neurodegeneration In Vivo In Rodents And In Human Tissue, François Xavier Lepelletier, Matthias Vandesquille, Marie Claude Asselin, Christian Prenant, Andrew C. Robinson, David M.A. Mann, Michael Green, Elizabeth Barnett, Samuel D. Banister, Marco Mottinelli, Christophe Mesangeau, Christopher R. Mccurdy, Inga B. Fricke, Andreas H. Jacobs, Michael Kassiou, Hervé Boutin
Evaluation Of 18F-Iam6067 As A Sigma-1 Receptor Pet Tracer For Neurodegeneration In Vivo In Rodents And In Human Tissue, François Xavier Lepelletier, Matthias Vandesquille, Marie Claude Asselin, Christian Prenant, Andrew C. Robinson, David M.A. Mann, Michael Green, Elizabeth Barnett, Samuel D. Banister, Marco Mottinelli, Christophe Mesangeau, Christopher R. Mccurdy, Inga B. Fricke, Andreas H. Jacobs, Michael Kassiou, Hervé Boutin
Faculty and Student Publications
© The author(s). This is an open access article distributed under the terms of the Creative Commons Attribution License (https://creativecommons.org/licenses/by/4.0/). See http://ivyspring.com/terms for full terms and conditions. The sigma 1 receptor (S1R) is widely expressed in the CNS and is mainly located on the endoplasmic reticulum. The S1R is involved in the regulation of many neurotransmission systems and, indirectly, in neurodegenerative diseases. The S1R may therefore represent an interesting neuronal biomarker in neurodegenerative diseases such as Parkinson's (PD) or Alzheimer's diseases (AD). Here we present the characterisation of the S1R-specific 18F-labelled tracer 18F-IAM6067 in two animal models and in human …
Efficacy Of Cpap Compared To Standard Pharmacotherapy In Reducing Cognitive Impairment Symptoms In Patients With Alzheimer's Disease, Nicholas Moylan
Efficacy Of Cpap Compared To Standard Pharmacotherapy In Reducing Cognitive Impairment Symptoms In Patients With Alzheimer's Disease, Nicholas Moylan
Capstone Showcase
This review analyzed the following question: In adults age 65 years old or older diagnosed with Alzheimer’s Disease (P), is nightly use of CPAP (I) more effective in reducing cognitive impairment symptoms (O) than standard pharmacotherapy options (C)? A literature search conducted through Google Scholar and PubMed granted six relevant articles that provided data for this review. No current studies compared CPAP treatment with pharmacotherapy, and each study used unique measures of cognitive function, making direct comparison of the two therapies difficult. Results demonstrated that first line pharmacotherapy can improve cognitive function, but only in limited way and only in …